Cognition Therapeutics has unveiled promising results from the Phase 2 COG1201 SHIMMER study of Zervimesine (CT1812) for dementia with Lewy bodies (DLB) at the recent AD/PD 2026 conference. The analysis revealed that Zervimesine treatment led to an impressive 86% reduction in decline on the Neuropsychiatric Inventory (NPI-12) compared to placebo, suggesting a potential disease-modifying effect. Additionally, the treatment showed favorable trends in cognitive fluctuations, memory, and daily living activities.

These findings are significant for the longevity and healthspan fields, as they highlight a potential therapeutic avenue for managing the complex behavioral and psychiatric symptoms associated with DLB. The company’s plans to move Zervimesine into late-stage trials for DLB psychosis, following positive discussions with the FDA, underscore its therapeutic promise and the growing interest in disease-modifying treatments for neurodegenerative conditions.

For those invested in aging research and therapeutic development, the full details of this study and its implications are worth exploring further on Cognition Therapeutics’ website.

Source: longevity.technology